newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

CBIO
  • Crescent Biopharma, Inc. (NASDAQ: CBIO) commenced an underwritten public offering of ordinary shares or pre-funded warrants on July 14, 2026.
  • The company intends to grant underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares at the public offering price.
  • Jefferies, TD Cowen, Guggenheim Securities, & Cantor serve as joint book-running managers, while LifeSci Capital acts as the passive book-running manager.
  • The offering is conducted pursuant to a shelf registration statement on Form S-3 declared effective by the SEC on July 10, 2026.
  • A preliminary prospectus supplement & accompanying prospectus will be filed with the SEC & copies are accessible via the SEC website.
  • Crescent Biopharma is a clinical-stage oncology company with a pipeline including a PD-1 x VEGF bispecific antibody & novel antibody-drug conjugates.
  • The offering remains subject to market conditions & customary closing conditions, with no assurance regarding completion, timing, size, or terms.